<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
    <channel>
      <title>AACR 2026 · 袁醫師個人閱讀簡報</title>
      <link>https://aacr2026-wiki.vercel.app</link>
      <description>最近的 10 條筆記 on AACR 2026 · 袁醫師個人閱讀簡報</description>
      <generator>Quartz -- quartz.jzhao.xyz</generator>
      <item>
    <title>Glossary Index</title>
    <link>https://aacr2026-wiki.vercel.app/glossary/README</link>
    <guid>https://aacr2026-wiki.vercel.app/glossary/README</guid>
    <description><![CDATA[ Glossary · 術語背景知識頁 所有術語頁都針對臨床醫師寫，先講「為什麼該知道」+「對臨床有什麼直接連結」，再補 mechanism。Length 200-400 字，點完就回章節繼續讀。 藥物類 (Modality) ADC · Antibody-Drug Conjugate TOP1i BiTE) PROTAC · Targeted Protein Degradation Molecular glue DALTAC CAR-NK Theranostic ASO · Antisense Oligonucleotide LNP · Lipid Nanoparticle 機制 / Targ... ]]></description>
    <pubDate>Thu, 23 Apr 2026 13:38:27 GMT</pubDate>
  </item><item>
    <title>CLAUDE</title>
    <link>https://aacr2026-wiki.vercel.app/CLAUDE</link>
    <guid>https://aacr2026-wiki.vercel.app/CLAUDE</guid>
    <description><![CDATA[ AACR 2026 Personal Wiki — Operating Manual Karpathy-pattern LLM wiki：Raw sources (scraped JSON) → narrative chapters → Obsidian vault。 目標對象：袁倫祥醫師（urologist + AI medical dev）。目標格式：narrative（讓知識留腦），不是 index。 路徑常量 名稱路徑VAULT~/Documents/aacr2026-wiki/QUARTZ~/Documents/aacr2026-quartz/ （build dir；content/... ]]></description>
    <pubDate>Thu, 23 Apr 2026 12:05:24 GMT</pubDate>
  </item><item>
    <title>log</title>
    <link>https://aacr2026-wiki.vercel.app/log</link>
    <guid>https://aacr2026-wiki.vercel.app/log</guid>
    <description><![CDATA[ log.md — append-only 操作紀錄 2026-04-23 上午 建立 VAULT skeleton：chapters/, sessions/, references/ 寫 CLAUDE.md operating manual：5 軸 SSOT + 4 個 / 指令（rescrape / chapter / lint / add-axis / query） Axis filter 跑完，存於 RAW/data/wiki_axes/*.json： prostate 436 · lung 1,110 · drug_dev 1,662 · fih 260 · ai_workflow 5... ]]></description>
    <pubDate>Thu, 23 Apr 2026 12:05:02 GMT</pubDate>
  </item><item>
    <title>AB#10007 · Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA </title>
    <link>https://aacr2026-wiki.vercel.app/references/10007</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10007</guid>
    <description><![CDATA[ Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG1 for recurrent glioblastoma Presenter: Keiko Shinjo, MD;PhD Session: First-in-Human Phase I Clinical Trials Time: 4/20/2026 9:00:00 AM → 4/20/2026 12:00:00 PM Authors Ryuta Saito 1 , Fumiharu Ohka... ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item><item>
    <title>AB#10028 · A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody c</title>
    <link>https://aacr2026-wiki.vercel.app/references/10028</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10028</guid>
    <description><![CDATA[ A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer Presenter: Sophia Frentzas, MD Session: Phase I Clinical Trials in Progress Time: 4/20/2026 9:00:00 AM → 4/20/2026 12:00:... ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item><item>
    <title>AB#10045 · Mechanisms of acquired resistance following dual EGFR/MET inhibition in MET-amplified EGFR TKI-resis</title>
    <link>https://aacr2026-wiki.vercel.app/references/10045</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10045</guid>
    <description><![CDATA[ Mechanisms of acquired resistance following dual EGFR/MET inhibition in MET-amplified EGFR TKI-resistant lung cancer Presenter: Yen-Ting Lin, MD;PhD Session: Late-Breaking Research: Experimental and Molecular Therapeutics 2 Time: 4/20/2026 2:00:00 PM → 4/20/2026 5:00:00 PM Authors Yen-Ting Lin 1 , Y... ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item><item>
    <title>AB#10082 · HZ-V055, an oral, highly potent pan-Ras molecular glue inhibitor demonstrated robust potency in Ras&lt;</title>
    <link>https://aacr2026-wiki.vercel.app/references/10082</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10082</guid>
    <description><![CDATA[ HZ-V055, an oral, highly potent pan-Ras molecular glue inhibitor demonstrated robust potency in RasMut cancer models Presenter: Yizhe Wu Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3 Time: 4/21/2026 2:00:00 PM → 4/21/2026 5:00:00 PM Authors Yizhe Wu 1 , Bo Feng 2 , Jiang... ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item><item>
    <title>AB#10088 · &lt;b&gt;Phase 1 study of HRS-6209, a highly selective CDK4 inhibitor, in patients with advanced solid tum</title>
    <link>https://aacr2026-wiki.vercel.app/references/10088</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10088</guid>
    <description><![CDATA[ Phase 1 study of HRS-6209, a highly selective CDK4 inhibitor, in patients with advanced solid tumors Presenter: Lin Dong Session: Phase 0 and First-in-Human Phase I Clinical Trials Time: 4/20/2026 2:00:00 PM → 4/20/2026 5:00:00 PM Authors Jiong Wu 1 , Jian Zhang 1 , Ning Lu 2 , Caigang Liu 3 , Qiang... ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item><item>
    <title>AB#10090 · Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma </title>
    <link>https://aacr2026-wiki.vercel.app/references/10090</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10090</guid>
    <description><![CDATA[ Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial Presenter: Regina Barragan Carrillo, MD Session: Phase I Clinical Trials Time: 4/21/2026 9:00:00 AM → 4/21/2026 12:00:00 PM Authors Regina Barragan Carrillo 1 , Migu... ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item><item>
    <title>AB#10123 · FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ s</title>
    <link>https://aacr2026-wiki.vercel.app/references/10123</link>
    <guid>https://aacr2026-wiki.vercel.app/references/10123</guid>
    <description><![CDATA[ FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress) Presenter: Gary Ulaner Session: Phase I Clinical Trials in Progress Time: 4/20/2026 9:00:00 AM → 4/20/2026 12:00:00 PM Authors Gary A. ]]></description>
    <pubDate>Thu, 23 Apr 2026 08:59:59 GMT</pubDate>
  </item>
    </channel>
  </rss>